Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Usage: AFINITOR is indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, progressive neuroendocrine tumors, advanced renal cell carcinoma, and various Tuberous Sclerosis Complex-related conditions, including renal angiomyolipoma, subependymal giant cell astrocytoma, and partial-onset seizures.
Usage: BETOPTIC S (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Usage: COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 2 years and older, ankylosing spondylitis in adults, non-radiographic axial spondyloarthritis in adults, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.
Usage: DESFERAL is indicated for treating acute iron intoxication and for managing chronic iron overload in patients with chronic anemia. It is not suitable for primary hemochromatosis, where phlebotomy is preferred.
Usage: DUREZOL® (difluprednate ophthalmic emulsion) 0.05% is indicated for treating inflammation and pain associated with ocular surgery and for the treatment of endogenous anterior uveitis.
Usage: ENTRESTO is indicated for reducing cardiovascular death and heart failure hospitalizations in adults with chronic heart failure, particularly those with low left ventricular ejection fraction. It is also used to treat symptomatic heart failure in pediatric patients aged one year and older, improving cardiovascular outcomes.
Usage: EXTAVIA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.